地西他滨联合CAG方案对老年急性髓系白血病患者的临床效果观察

Clinical Effect Observation of Decitabine Combined with CAG Regimen on Elderly Patients with Acute Myeloid Leukemia

目的观察地西他滨联合CAG方案对老年急性髓系白血病患者的临床效果。方法选取2018年1月至2019年12月期间,于我院就诊的老年急性髓系白血病患者80例作研究对象,按照不同治疗方法将其分为观察组(n=40例)与参照组(n=40例),予以参照组CAG方案治疗,观察组应用地西他滨联合CAG方案治疗。结果观察组的临床总有效率(70.00%)高于参照组(52.50%),组间差异显著(P<0.05);观察组的不良反应总发生率为15.00%,低于参照组的37.50%,统计学有意义(P<0.05)。观察组治疗后骨髓原始细胞比例、PDGF低于参照组,血小板、血红蛋白高于参照组(P<0.05)。观察组患者治疗后,其生存时间为(22.08±2.96)个月;参照组为(14.59±3.08)个月。结论地西他滨联合CAG方案对老年急性髓系白血病患者的治疗效果较显著,且不良反应少,应用价值较高。

Objective to observe clinical effect of decitabine combined with CAG on elderly patients with acute myeloid leukemia.Methods choose 80 cases elderly patients with acute myeloid leukemia in our hospital from January 2018 to December 2019 as research objects,divide them into observation group(n=40 cases)and reference group according to different treatment methods(n=40 cases),reference group was treated with CAG regimen,and observation group with decitabine combined with CAG regimen.Results total clinical effective rate(70.00%)of observation group was higher than reference group(52.50%),difference was significant between groups(P<0.05);total incidence of adverse reactions in observation group was 15.00%,lower than 37.50%of reference group,with statistical significance,(P<0.05).After treatment,ratio of bone marrow blasts and PDGF in observation group was lower than reference group,platelets and hemoglobin were higher than reference group(P<0.05).After treatment,survival time of observation group was(22.08±2.96)months;that of reference group was(14.59±3.08)months.Conclusion decitabine combined with CAG has significant curative effect on elderly patients with acute myeloid leukemia,with few adverse reactions and high application value.